|GRANTWAY
EN

Advancing Psychedelics Research for Treating Addiction (R61/R33 Clinical Trial Required)

National Institutes of Health

Share
Favorite
Feedback
Summary
-
02 November 2023
-
-
-
For profit
Not for profit (incl. NGOs)
Public sector
R&D and Higher Education
-
Education, Skills Building and Training Health, Justice and Social Welfare Research, Development and Innovation
Overview

The purpose of this FOA is to use multidisciplinary approaches to advance basic and clinical research and address key knowledge gaps on psychedelics. Given the therapeutic promise that psychedelics hold as neurotherapeutics, the goal is to systematically evaluate, and understand their mechanism of action and drug-target engagement, along with other translational aspects including their safety, pharmacokinetics/pharmacodynamics, and efficacy, in the context of substance use disorders (SUD).

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Learn more or apply
All information about this funding has been collected from and belongs to the funding organization
19 May 2023